A prospective single center investigator initiated trial to evaluate the changes of intercellular spaces after proton pump inhibitor treatment in patients with erosive reflux disease

Asan Medical Center0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年8月30日

适应症

试验速览

暂无简介。

•1) Those who have been diagnosed with erosive reflux esophagitis and are over the age of 19 who are scheduled to undergo esophageal resection, and are under 75 years of age
•2) Those who have had erosive reflux esophagitis LA-Aor above on EGD within the last 1 year
•3) Those who have symptome of heartburn or acid regurgitation
•4) Those who have been informed and consented to this study

•1) Non erosive reflux esophagitis
•2) Barrett`s esophagus >2cm
•3) Esophageal varix
•4) Those who have coagulopathy (Platelet <50K , PT< 60% , aspirin/warfarin )
•5) Pregnant or lactating females
•6) Those who have previously had esophageal/stomach resection or gastric acid secretion suppression surgery
•7) Patients who have taken H2-receptor antagonist or PPI within 2 weeks before screening gastroesophageal endoscopy (EGD)
•8) Patients with hypersensitivity reactions to S-pantoprazole or benzimidazoles and a history of such reactions
•9) Patients who have taken the following drugs within 2 weeks prior to the first dose of the study drug, or who need to be continuously treated with the following drugs
•* Theophylline, Bismuth salts, Warfarin, Phenytoin, Barbiturates, Antineoplastic agents, Erythromycin, Clarithromycin, Sucralfate, Rilpivirine, Atazanavir, Nelfinavir
•10) AST),ALT, ALP > 3.0 × upper limit of normal (ULN) of the study site

发起方